Stock DTIL PRECISION BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Precision BioSciences, Inc.

Equities

DTIL

US74019P2074

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-16 pm EDT 		5-day change 1st Jan Change
12.87 USD -1.45% Intraday chart for Precision BioSciences, Inc. -7.01% +17.53%
Apr. 16 Precision BioSciences Opts to Regain Rights to 3 Programs From Eli Lilly Unit Collaboration MT
Mar. 27 Precision BioSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Precision BioSciences Opts to Regain Rights to 3 Programs From Eli Lilly Unit Collaboration
MT
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
BU
Precision BioSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Precision BioSciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Precision BioSciences: Q4 Earnings Snapshot
AQ
Earnings Flash (DTIL) PRECISION BIOSCIENCES Posts Q4 Revenue $7M
MT
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
BU
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
BU
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy
BU
IECURE SECURES APPROVAL FROM U.K. MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY TO EXPAND THE OTC-HOPE STUDY OF ECUR-506
AQ
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
BU
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
CI
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants
AQ
Precision BioSciences Launches $40 Million Public Offering; Shares Slump
MT
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants
BU
Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants
BU
Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences
BU
Precision BioSciences, Inc. Announces Non-Exclusive Patent License Agreement with Caribou Biosciences
CI
Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness
BU
Precision BioSciences, Inc. Receives Pre-IND Feedback from US FDA for PBGENE-HBV as It Advances Towards Clinical Readiness
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DTIL Stock
  4. News Precision BioSciences, Inc.